Investor Overview

Webcast ImageWebcast
Histogenics Corp Investor Day (Replay)
06/19/18 at 8:15 a.m. ET
Histogenics Corp Investor Day
Tuesday, June 19, 2018 8:15 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Histogenics is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.81
Change (%) Stock is Down 0.08 (2.77%)
Volume77,534
Data as of 06/22/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent NewsMore >>
DateTitle 
05/31/18Histogenics Corporation to Host Investor Day on June 19, 2018
WALTHAM, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Histogenics will host its first Investor Day on Tuesday, June 19, 2018, in New York City. Members of Histogenics’ management team will provide a corporate overview and discuss the commercialization plan for NeoCart®, Histogenics’ lead investigational product, designed to reb... 
Printer Friendly Version
05/10/18Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results
‒ Top-line Superiority Data from NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rap... 
Printer Friendly Version
04/26/18Histogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter 2018 financial results on May 10, 2018, before the U.S. financial markets open.  The Company will host a conference call on Thursday, May 10, 2018 at 8:30 a.m. EDT.  To access the live call, please dial (877) 930-8064 (domestic) or (253) 336-... 
Printer Friendly Version
04/18/18Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors
Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of Susan Washer to its Board of Directors.  “Having known and worked with Sue for over 15 years, we are extremely pleased to welcome her to Hi... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.